Am J Pharmacol | Volume 2, Issue 1 | Research Article | Open Access
Shah Murad1*, Azmi AA2, Shahina Hakro3, Adnan Shafique4 and Abdul Ghaffar5
1Department of Pharmacology, Danth and Islamabad Medical & Dental College, Pakistan
2Department of Pharmacology, Islam Medical College, Pakistan
3Department of Pharmacology, Karachi Institute of Medical Sciences, Pakistan
4Department of Pharmacology, Medicine Coordination Cell (MCC), Pakistan
5Department of Pharmacology, Islamabad Medical & Dental College, Pakistan
*Correspondance to: Shah Murad
Fulltext PDFWhen it comes to cholesterol, there are two terms worth knowing. Hyperlipidemia means your blood has too many lipids (or fats), such as cholesterol and triglycerides. One type of hyperlipidemia, hypercholesterolemia, and means there’s too much LDL (bad) cholesterol in your blood. This condition increases fatty deposits in arteries and the risk of blockages. Reduction in dietary cholesterol levels produces regression of atherosclerosis and restores endothelium-dependent relaxation of extra cranial arteries toward normal in experimental animals. Susceptibility to vasoconstriction in response to activation of platelets and leukocytes is reduced or abolished by regression of atherosclerosis. Design and Place of Conduction: The research work was single blind placebo-controlled, conducted at Jinnah Hospital, Lahore. Research Time: It was conducted from April 2018 to October 2018. Number of Patients and their Age: Seventy five already diagnosed primary and secondary hyperlipidemic patients were selected with age range from 17 years to 65 years. Exclusion criteria: Diabetes mellitus, cigarette smoking/alcohol addictive patients, peptic ulcer disease, hypothyroidism, kidney dysfunction, any heart disease and liver disease. All patients were divided in three groups (group-I, group-II, group-III), 25 in each group. Proforma for Patients: Their baseline lipid profile data were taken and filed in specifically designed Performa, at start of taking medicine. Patient's Group Division: Twenty five patients of group-I were advised to take 10 grams of Flaxseeds in three divided doses after meal. Twenty five patients of group-II were advised to take Ajwain seeds 10 grams in three divided doses after each meal for two months. Twenty five patients of group-III were provided placebo capsules, (containing grinded rice), taking one capsule after each meal. All participants were advised to take these medicines for eight weeks. Follow up Period: All participants were called fortnightly for their query and follow up. Their LDLcholesterol and HDL-cholesterol was determined at the hospital laboratory. Results: In two months therapy by Flaxseeds decreased LDL-cholesterol from 195.11 ± 2.11 mg/ dl to 190.22 ± 3.11 mg/dl, which is significant statistically. HDL was increased from 34.53 ± 1.65 mg/dl to 38.97 ± 2.29 mg/dl, which is also significant change. In two months therapy by Ajwain, LDL-c reduced from 201.51 ± 2.62 mg/dl to 197.11 ± 2.66 mg/dl, which is significant statistically. HDL-cholesterol increased by Ajwain from 36.97 ± 3.32 mg/dl to 37.45 ± 1.87 mg/dl, which is insignificant statistically. Conclusion: It was concluded from this study that Ajwain and Flaxseeds reduces LDL-cholesterol moderately. Flaxseeds have more effect on HDL-c but Ajwain has lowest effect on this parameter.
Murad S, Azmi AA, Hakro S, Shafique A, Ghaffar A. How Plant Seeds Work?. Am J Pharmacol. 2019; 2(1): 1015.